Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| SL Seek LabsCompany profile Develops a programmable disease response platform to detect protect and counter disease threats Develops a programmable disease response platform to detect protect and counter disease threats | $2M | GrantUndisclosed | Biotech | United States | Investors | |
| G GelMEDIXCompany profile Develops regenerative therapies to restore vision by regenerating damaged retinal cells Develops regenerative therapies to restore vision by regenerating damaged retinal cells | $13M | Seed | Biotech | United States | Investors | |
| B Provides AI-powered platform for bioprocess development and optimization | Undisclosed | StrategicUndisclosed | Biotech | United States | Investors | |
| OM OncoRes MedicalCompany profile Develops a hand-held real-time intraoperative imaging device to improve the detection of residual cancer during surgery Develops a hand-held real-time intraoperative imaging device to improve the detection of residual cancer during surgery | $27M | Growth | Biotech, Healthtech | Australia | Investors | |
| TB The Biological ComputingCompany profile Integrates living neurons with AI for more efficient computing Integrates living neurons with AI for more efficient computing | $25M | Seed | Biotech, Healthtech | United States | Investors | |
| L Loyal develops medicines intended to extend dogs’ lifespans. | $100M | Series CSeries C+ | Biotech | United States | Investors | |
| AO Atlas Oncology PartnersCompany profile Delivers uplifting and responsive cancer care during and beyond treatment Delivers uplifting and responsive cancer care during and beyond treatment | $28M | Series A | Biotech, Healthtech | United States | Investors | |
 4Moving BiotechCompany profile Clinical-stage development of a locally delivered GLP-1 therapy for inflammatory knee osteoarthritis. Clinical-stage development of a locally delivered GLP-1 therapy for inflammatory knee osteoarthritis. | €12M | Debt and equity financingUndisclosed | Biotech | France | Investors Undisclosed | |
| A ArrayPatchCompany profile Develops microneedle-based therapeutics for treatment of nail fungus and other diseases Develops microneedle-based therapeutics for treatment of nail fungus and other diseases | €3M | Seed | Biotech, Healthtech | Ireland | Investors | |
| IB Developing a next-generation pertussis vaccine candidate BPZE1 | $115M | Series B | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.